<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T06:49:05Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4837384" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4837384</identifier>
        <datestamp>2016-05-09</datestamp>
        <setSpec>rcpsychsd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Psychiatry</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br J Psychiatry</journal-id>
              <journal-id journal-id-type="hwp">bjprcpsych</journal-id>
              <journal-title-group>
                <journal-title>The British Journal of Psychiatry</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0007-1250</issn>
              <issn pub-type="epub">1472-1465</issn>
              <publisher>
                <publisher-name>Royal College of Psychiatrists</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4837384</article-id>
              <article-id pub-id-type="pmcid">PMC4837384</article-id>
              <article-id pub-id-type="pmc-uid">4837384</article-id>
              <article-id pub-id-type="pmid">26294368</article-id>
              <article-id pub-id-type="doi">10.1192/bjp.bp.114.154997</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Papers</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Non-replication of the association between 5HTTLPR and response to psychological therapy for child anxiety disorders</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lester</surname>
                    <given-names>Kathryn J.</given-names>
                  </name>
                  <xref ref-type="author-notes" rid="fn1">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Roberts</surname>
                    <given-names>Susanna</given-names>
                  </name>
                  <xref ref-type="author-notes" rid="fn1">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keers</surname>
                    <given-names>Robert</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Coleman</surname>
                    <given-names>Jonathan R. I.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Breen</surname>
                    <given-names>Gerome</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wong</surname>
                    <given-names>Chloe C. Y.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Xu</surname>
                    <given-names>Xiaohui</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Arendt</surname>
                    <given-names>Kristian</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Blatter-Meunier</surname>
                    <given-names>Judith</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bögels</surname>
                    <given-names>Susan</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cooper</surname>
                    <given-names>Peter</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Creswell</surname>
                    <given-names>Cathy</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Heiervang</surname>
                    <given-names>Einar R.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Herren</surname>
                    <given-names>Chantal</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hogendoorn</surname>
                    <given-names>Sanne M.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hudson</surname>
                    <given-names>Jennifer L.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Krause</surname>
                    <given-names>Karen</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lyneham</surname>
                    <given-names>Heidi J.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McKinnon</surname>
                    <given-names>Anna</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morris</surname>
                    <given-names>Talia</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nauta</surname>
                    <given-names>Maaike H.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rapee</surname>
                    <given-names>Ronald M.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rey</surname>
                    <given-names>Yasmin</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schneider</surname>
                    <given-names>Silvia</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schneider</surname>
                    <given-names>Sophie C.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Silverman</surname>
                    <given-names>Wendy K.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Patrick</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thastum</surname>
                    <given-names>Mikael</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thirlwall</surname>
                    <given-names>Kerstin</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Waite</surname>
                    <given-names>Polly</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wergeland</surname>
                    <given-names>Gro Janne</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Eley</surname>
                    <given-names>Thalia C.</given-names>
                  </name>
                  <xref ref-type="corresp" rid="cor1"/>
                </contrib>
                <aff><bold>Kathryn J. Lester</bold>, DPhil, School of Psychology, University of Sussex, and King's College London, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK; <bold>Susanna Roberts</bold>, MSc, King's College London, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK; <bold>Robert Keers</bold>, PhD, King's College London, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK; <bold>Jonathan R. I. Coleman</bold>, MSc, King's College London, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK; <bold>Gerome Breen</bold>, PhD, King's College London, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK and National Institute for Health Research Biomedical Research Centre, South London and Maudsley National Health Service Trust, UK; <bold>Chloe C. Y. Wong</bold>, PhD, King's College London, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK; <bold>Xiaohui Xu</bold>, MD, King's College London, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK; <bold>Kristian Arendt</bold>, MSc, Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, The Netherlands; <bold>Judith Blatter-Meunier</bold>, PhD, Department of Psychology, University of Basel, Basel, Switzerland; <bold>Susan Bögels</bold>, PhD, Research Institute Child Development and Education, University of Amsterdam, The Netherlands; <bold>Peter Cooper</bold>, DPhil, School of Psychology and Clinical Language Sciences, University of Reading, UK and Department of Psychology, Stellenbosch University, South Africa; <bold>Cathy Creswell</bold>, DClinPsy, PhD, School of Psychology and Clinical Language Sciences, University of Reading, UK; <bold>Einar R. Heiervang</bold>, MD PhD, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; <bold>Chantal Herren</bold>, PhD, Department of Forensic Psychiatry, University of Basel Psychiatric Clinics, Basel, Switzerland; <bold>Sanne M. Hogendoorn</bold>, PhD, Department of Child and Adolescent Psychiatry/De Bascule, Academic Medical Centre, Amsterdam, The Netherlands; <bold>Jennifer L. Hudson</bold>, PhD, Department of Psychology, Centre for Emotional Health, Macquarie University, Sydney, Australia; <bold>Karen Krause</bold>, DiplPsych, Department of Psychology, Ruhr-Universität Bochum, Bochum, Germany; <bold>Heidi J. Lyneham</bold>, PhD, Department of Psychology, Centre for Emotional Health, Macquarie University, Sydney, Australia; <bold>Anna McKinnon</bold>, PhD, Brain and Mind Research Institute, University of Sydney, Sydney, Australia, and The MRC Cognition and Brain Sciences Unit, Cambridge, UK; <bold>Talia Morris</bold>, BPsych(Hons), Department of Psychology, Centre for Emotional Health, Macquarie University, Sydney, Australia; <bold>Maaike H. Nauta</bold>, PhD, Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, The Netherlands; <bold>Ronald M. Rapee</bold>, PhD, Department of Psychology, Centre for Emotional Health, Macquarie University, Sydney, Australia; <bold>Yasmin Rey</bold>, PhD, Child Anxiety and Phobia Program, Department of Psychology, Florida International University, Miami, USA; <bold>Silvia Schneider</bold>, PhD, Department of Psychology, Ruhr-Universität Bochum, Bochum, Germany; <bold>Sophie C. Schneider</bold>, BPsych(Hons), Department of Psychology, Centre for Emotional Health, Macquarie University, Sydney, Australia; <bold>Wendy K. Silverman</bold>, PhD, Yale University School of Medicine, Child Study Center, New Haven, Connecticut, USA; <bold>Patrick Smith</bold>, PhD, King's College London, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, London, UK; <bold>Mikael Thastum</bold>, PhD, Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark; <bold>Kerstin Thirlwall</bold>, DClinPsy, School of Psychology and Clinical Language Sciences, University of Reading, UK; <bold>Polly Waite</bold>, DClinPsy, School of Psychology and Clinical Language Sciences, University of Reading, UK; <bold>Gro Janne Wergeland</bold> MD, Department of Child and Adolescent Psychiatry, Haukeland University Hospital, Bergen, Norway; <bold>Thalia C. Eley</bold>, PhD, King's College London, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><bold>Correspondence:</bold> Thalia C. Eley, SGDP Centre, Institute of Psychiatry, King's College, Box PO80, London SE5 8AF, UK. Email: <email>thalia.eley@kcl.ac.uk</email></corresp>
                <fn id="fn1">
                  <label>*</label>
                  <p id="P1">Joint first authors.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>2</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <month>2</month>
                <year>2016</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
              <volume>208</volume>
              <issue>2</issue>
              <fpage>182</fpage>
              <lpage>188</lpage>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>7</month>
                  <year>2014</year>
                </date>
                <date date-type="rev-recd">
                  <day>8</day>
                  <month>12</month>
                  <year>2014</year>
                </date>
                <date date-type="accepted">
                  <day>11</day>
                  <month>12</month>
                  <year>2014</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Royal College of Psychiatrists 2016.</copyright-statement>
                <copyright-year>2016</copyright-year>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
                  <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) licence.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="182.pdf"/>
              <abstract>
                <p id="P3">
                  <bold>Background</bold>
                </p>
                <p id="P4">We previously reported an association between 5HTTLPR genotype and outcome following cognitive–behavioural therapy (CBT) in child anxiety (Cohort 1). Children homozygous for the low-expression short-allele showed more positive outcomes. Other similar studies have produced mixed results, with most reporting no association between genotype and CBT outcome.</p>
                <p id="P5">
                  <bold>Aims</bold>
                </p>
                <p id="P6">To replicate the association between 5HTTLPR and CBT outcome in child anxiety from the Genes for Treatment study (GxT Cohort 2, n = 829).</p>
                <p id="P7">
                  <bold>Method</bold>
                </p>
                <p id="P8">Logistic and linear mixed effects models were used to examine the relationship between 5HTTLPR and CBT outcomes. Mega-analyses using both cohorts were performed.</p>
                <p id="P9">
                  <bold>Results</bold>
                </p>
                <p id="P10">There was no significant effect of 5HTTLPR on CBT outcomes in Cohort 2. Mega-analyses identified a significant association between 5HTTLPR and remission from all anxiety disorders at follow-up (odds ratio 0.45, <italic>P</italic> = 0.014), but not primary anxiety disorder outcomes.</p>
                <p id="P11">
                  <bold>Conclusions</bold>
                </p>
                <p id="P12">The association between 5HTTLPR genotype and CBT outcome did not replicate. Short-allele homozygotes showed more positive treatment outcomes, but with small, non-significant effects. Future studies would benefit from utilising whole genome approaches and large, homogenous samples.</p>
              </abstract>
              <funding-group>
                <award-group id="funding-1">
                  <funding-source>Medical Research Council</funding-source>
                  <award-id>G0901874/1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Eley</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>UK Medical Research Council</funding-source>
                  <funding-source>Jacobs Foundation Young Scholar</funding-source>
                  <award-id>MR/J011762/1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Lester</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>UK Medical Research Council Population Health fellowship</funding-source>
                  <award-id>MR/K021281/1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Keers</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-4">
                  <funding-source>Australian Research Council</funding-source>
                  <award-id>DP0878609</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Hudson</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Rapee</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Eley</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-5">
                  <funding-source>Australian NHMRC</funding-source>
                  <award-id>1027556</award-id>
                  <award-id>488505</award-id>
                  <award-id>382008</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Rapee</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Hudson</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Lyneham</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Mihalopolous</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-6">
                  <funding-source>TrygFonden</funding-source>
                  <award-id>7-10-1391</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Thastum</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Hougaard</surname>
                      <given-names>Esben</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-7">
                  <funding-source>Edith ogGodtfred Kirk Christiansens Fond</funding-source>
                  <award-id>21-5675</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Thastum</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-8">
                  <funding-source>Swiss National Science Foundation</funding-source>
                  <award-id>105314-116517</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Schneider</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-9">
                  <funding-source>Western Norway Regional Health Authority</funding-source>
                  <award-id>911253</award-id>
                  <award-id>911366</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Havik</surname>
                      <given-names>Odd</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Heiervang</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-10">
                  <funding-source>UK Medical Research Council Clinical Fellowship</funding-source>
                  <award-id>G0802821</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Meiser-Stedman</surname>
                      <given-names>Richard</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-11">
                  <funding-source>NIMH R01</funding-source>
                  <award-id>MH079943</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Silverman</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-12">
                  <funding-source>UK NIHR</funding-source>
                  <award-id>PB-PG-0110-21190</award-id>
                  <award-id>PB-PG-0107-12042</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Creswell</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Cooper</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-13">
                  <funding-source>UK Medical Research Council</funding-source>
                  <award-id>09-800-17</award-id>
                  <award-id>G0802326</award-id>
                  <award-id>G1002011</award-id>
                  <award-id>G0601874</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Cooper</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Creswell</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Waite</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-14">
                  <funding-source>MRC-NIHR</funding-source>
                </award-group>
                <award-group id="funding-15">
                  <funding-source>UK NIHR</funding-source>
                  <award-id>PB-PG-0110-21190</award-id>
                  <award-id>PB-PG-0107-12042</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Creswell</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Cooper</surname>
                      <given-names/>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>McIntosh</surname>
                      <given-names>Emma</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Willetts</surname>
                      <given-names>Lucy</given-names>
                    </name>
                  </principal-award-recipient>
                  <principal-award-recipient>
                    <name>
                      <surname>Sheffied</surname>
                      <given-names>Paul</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-16">
                  <funding-source>National Institute for Health Research (NIHR)</funding-source>
                </award-group>
                <award-group id="funding-17">
                  <funding-source>Biomedical Research Centre at South London</funding-source>
                </award-group>
                <award-group id="funding-18">
                  <funding-source>Maudsley NHS Foundation Trust</funding-source>
                </award-group>
                <award-group id="funding-19">
                  <funding-source>King's College London</funding-source>
                </award-group>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <p id="P13">Anxiety disorders represent a significant global health burden due to their debilitating nature and high lifetime prevalence.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> They frequently occur early and show high continuity into adulthood.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Cognitive–behavioural therapy (CBT) is the most established treatment option for childhood anxiety, with around 59% of children remitting following treatment.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> The short, low-expression allele of the functional serotonin transporter promoter polymorphism, 5HTTLPR, has been associated with heightened anxiety and related traits<sup><xref rid="R4" ref-type="bibr">4</xref></sup> compared with the long allele, although findings are somewhat mixed.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> Gene–environment interaction studies provide evidence that short allele carriers have the poorest outcomes in high stress environments,<sup><xref rid="R7" ref-type="bibr">7</xref></sup> but also show the largest benefit in response to low stress or enriching environments.<sup><xref rid="R8" ref-type="bibr">8</xref>–<xref rid="R11" ref-type="bibr">11</xref></sup> These findings suggest that 5HTTLPR may represent a ‘differential susceptibility’ marker, which acts ‘for better and for worse’.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Some individuals who are more susceptible to the negative effects of poor environments might also be more sensitive to the positive effects of an enriching experience,<sup><xref rid="R13" ref-type="bibr">13</xref></sup> and therefore may respond better to the supportive influence provided by psychological therapies. The field of ‘therapygenetics’ – genetic predictors of outcome following purely psychological therapies – is relatively new.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> In a previous study, we found that 5HTTLPR genotype was significantly associated with CBT outcome.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> SS homozygotes showed a significantly greater reduction in symptom severity than long allele carriers, and were 20% (18.8%) more likely to be free of their primary (all) anxiety disorder diagnoses by follow-up. A handful of other studies have investigated 5HTTLPR and outcomes following a range of psychological therapies, although results have not been consistent.<sup><xref rid="R15" ref-type="bibr">15</xref>–<xref rid="R23" ref-type="bibr">23</xref></sup> Two studies also found the SS genotype to be associated with more positive outcomes; following a problem-solving intervention with antidepressants in older adults with post-stroke depression,<sup><xref rid="R16" ref-type="bibr">16</xref></sup> and exposure-based therapy in adults with panic disorder with agoraphobia.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> However, a third study examining CBT in post-traumatic stress disorder found poorer outcomes in SS carriers.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Additional studies in both adults and children found no effect of 5HTTLPR outcome following psychological interventions. Of note, these studies are all of small sample size, and are generally underpowered to detect what is likely to be a small effect of 5HTTLPR genotype. Furthermore, participants in many of the studies were also on concurrent antidepressant or anxiolytic medications. These factors highlight the need for replication in a large sample to further examine the association between 5HTTLPR genotype and outcome following a purely psychological therapy.</p>
            <p id="P14">Based on our previous research, the aim of this study was to test whether 5HTTLPR genotype was associated with outcome following CBT in a large replication sample of 829 children with anxiety disorders. This sample size far exceeded that required to detect an effect of similar magnitude to that of our previously reported findings, with greater than 95% power at a significance level of α&lt;0.01. We hypothesised that children with the SS genotype would (a) show greater rates of remission at follow-up and (b) show a greater reduction in symptom severity at follow-up than those with the SL or LL genotype. To further increase power to detect an association between 5HTTLPR genotype and outcome and to estimate an upper bound for the magnitude of the effect, mega-analyses were performed on a combined data-set comprising both our discovery (<italic>n</italic> = 496) and replication samples (<italic>n</italic> = 829). Again, we hypothesised that SS genotype carriers would show a more positive outcome following treatment relative to SL or LL genotype carriers.</p>
            <sec sec-type="methods" id="S1">
              <title>Method</title>
              <sec sec-type="intro" id="S2">
                <title>Study overview</title>
                <p id="P15">All participants come from the Genes for Treatment (GxT) study, an international multisite collaboration designed to identify clinical, demographic and genetic predictors of outcome following CBT for child anxiety.<sup><xref rid="R24" ref-type="bibr">24</xref></sup></p>
              </sec>
              <sec sec-type="subjects" id="S3">
                <title>Participants and treatment</title>
                <p id="P16">Participants aged between 5 and 18 years (mean age: 10 years) met DSM-IV criteria for primary diagnosis of an anxiety disorder. Exclusion criteria included significant physical/intellectual impairment, psychoses and concurrent treatment. All participants completed a full course of CBT either as part of a trial or as treatment as usual at one of 11 sites; Sydney, Australia (<italic>n</italic> = 293); Reading, UK (<italic>n</italic> = 199); Aarhus, Denmark (<italic>n</italic> = 112); Bergen, Norway (<italic>n</italic> = 35); Bochum, Germany (<italic>n</italic> = 50); Florida, USA (<italic>n</italic> = 36); Basel, Switzerland (<italic>n</italic> = 46); Groningen, The Netherlands (<italic>n</italic> = 35); Oxford, UK (<italic>n</italic> = 11); Cambridge, UK (<italic>n</italic> = 9) and Amsterdam, The Netherlands (<italic>n</italic> = 3). All treatments were manualised and treatment protocols across sites were comparable for core elements of CBT, including teaching of coping skills, cognitive restructuring and exposure. Treatment modalities fell into three broad groups – individual CBT (39.8%), group-based CBT (46.1%) and parent-supported guided self-help (14.1%). Further sample characteristics and site-specific trial details can be found in the online data supplement to this article.</p>
              </sec>
              <sec id="S4">
                <title>Measures</title>
                <sec id="S5">
                  <title>Anxiety disorder diagnoses</title>
                  <p id="P17">Anxiety disorders were assessed at three time points; before and after treatment, and at follow-up (3, 6 or 12 months after conclusion of treatment). Diagnoses were made with the Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV-C/P)<sup><xref rid="R25" ref-type="bibr">25</xref></sup> at all sites except for Bochum and Basel, where the German equivalent (Kinder-DIPs) was used.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> Clinical severity ratings (CSRs) were usually based on composite parent and child reports, and were assigned on a scale of 0–8 (see Hudson <italic>et al</italic><sup><xref rid="R24" ref-type="bibr">24</xref></sup> for further details). A diagnosis was made when the child met diagnostic criteria and received a CSR of 4 or more. Primary diagnoses included generalised anxiety disorder (GAD; 34.9%), separation anxiety disorder (SAD; 25.1%), social anxiety disorder (20.8%), specific phobias (11.9%), panic disorder (3.3%), obsessive–compulsive disorder (OCD; 2.1%), post-traumatic stress disorder (PTSD; 1.3%), selective mutism (0.2%, in the cases with primary selective mutism, a diagnosis of severe social phobia was also given; the selective mutism was considered by the clinician to be primary, the most interfering), and anxiety disorders not otherwise specified (ADNOS; 0.5%).</p>
                </sec>
                <sec id="S6">
                  <title>Ethnicity</title>
                  <p id="P18">Ethnicity was determined by parent-report regarding the ancestry of the child's grandparents. Those with four grandparents of reported White European ancestry were included in the ‘White European subset’ (<italic>n</italic> = 560, see online data supplement).</p>
                </sec>
              </sec>
              <sec id="S7">
                <title>Sample collection and genotyping</title>
                <p id="P19">DNA samples were collected using either buccal swabs or Oragene saliva kits (DNA Genotek, Ottawa, Canada) and extracted using established procedures.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> 5HTTLPR was genotyped using polymerase chain reaction amplification and agarose gel electrophoresis according to published protocols.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> A selection of samples (<italic>n</italic> = 40) were genotyped in duplicate, with consistent results for each attempt. The genotypic distribution of the sample conformed to Hardy–Weinberg proportions (LL: 25.9%, SL: 51.4%, SS: 22.7%; χ<sup>2</sup><sub>1</sub> = 0.69, <italic>P</italic> = 0.444).</p>
              </sec>
              <sec id="S8">
                <title>Ethical approval</title>
                <p id="P20">All trials and collection of samples were approved by site-specific human ethics and biosafety committees. Parents provided informed consent, children assent. The storage and analysis of DNA was approved by the King's College London Psychiatry, Nursing and Midwifery Research Ethics Sub-Committee.</p>
              </sec>
              <sec id="S9">
                <title>Sample size and power analyses</title>
                <p id="P21">Participants used in this paper are referred to as Cohort 2, which consisted of 829 participants with clinical data available both at baseline and at least one outcome time-point (post-treatment, a follow-up time-point or both). However, of these, 792 had outcome data at post-treatment; 606 at follow-up.</p>
                <p id="P22">Power calculations<sup><xref rid="R29" ref-type="bibr">29</xref></sup> suggested a sample size of 285 would be required for 95% power to detect an effect of similar magnitude to our previously reported findings (Cohort 1, odds ratio (OR) = 0.4), at a significance level of α = 0.01 using a recessive allelic model. Our sample of &gt;600 has &gt;90% power to detect a smaller effect size (OR = 0.6) at a significance level of α = 0.01, and 80% power to detect an even smaller effect size of OR = 0.7 at α = 0.05.</p>
              </sec>
              <sec id="S10">
                <title>Data analysis</title>
                <sec id="S11">
                  <title>Definition of outcome variables</title>
                  <p id="P23">Treatment outcome was defined in a number of ways. Participants were first classed as remitters or non-remitters based on the presence or absence of their primary anxiety disorder diagnosis (primary anxiety remission). Treatment remission was measured both at post-treatment, and at follow-up (collapsed to include all follow-up time-points; 3, 6 or 12 months). Remission was also categorised as the absence of all anxiety disorder diagnoses at post-treatment and at follow-up (all anxiety response). Finally, treatment response was defined as the change in primary anxiety disorder severity from pre- to post-treatment, and from pre-treatment to follow-up.</p>
                </sec>
                <sec id="S12">
                  <title>Mixed effects models</title>
                  <p id="P24">To investigate the effect of 5HTTLPR genotype on remission, logistic mixed effects models were used including treatment trial as a higher order random effect. For consistency with the statistical analyses used in our previous study, 5HTTLPR genotype was defined by a recessive model, where SS was coded as 1 and SL/LL were coded as 0. Gender, age and baseline severity were included as covariates in all analyses (age and baseline severity centred at the mean). Analyses were conducted for primary anxiety diagnosis remission and all anxiety disorder diagnoses remission separately at post-treatment and at follow-up. Models focusing on the follow-up time-point included the linear and quadratic effects of time as covariates.</p>
                  <p id="P25">Linear mixed effects models were used to investigate the effect of 5HTTLPR genotype on response (change in primary anxiety disorder severity). Again, trial was included as a higher order random effect, and gender, age and baseline severity were included as covariates. Time was included as a covariate for the model testing change from pre- to post-treatment; and both linear and quadratic effects of time were included as covariates in the model for follow-up.</p>
                </sec>
                <sec id="S13">
                  <title>Mega-analyses</title>
                  <p id="P26">Finally, logistic and linear mixed models were run using participants from both Cohort 1<sup><xref rid="R15" ref-type="bibr">15</xref></sup> and Cohort 2 combined. A total of 584 samples were genotyped in Cohort 1, from children (aged 6–13) who received CBT for an anxiety disorder. In this sample, 496 had sufficient outcome data to be included in at least one analysis. The sample size of 359 reported in Eley <italic>et al</italic><sup><xref rid="R8" ref-type="bibr">8</xref></sup> refers to the White European participants included in the main analysis of response to therapy at follow-up. Further participants were included in analyses of response to therapy at post-treatment, with a total of 496 included in at least one analysis. Participants included in Cohort 1 were recruited at two sites: Sydney, Australia and Reading, UK. Participants who were genotyped in Cohort 1 but whose clinical data were not available at the time of submission were included in Cohort 2. Combining both cohorts increased the sample size, and so the power to detect an association between 5HTTLPR genotype and outcome. Cohort was included as a covariate in these analyses.</p>
                </sec>
                <sec id="S14">
                  <title>Multiple testing corrections</title>
                  <p id="P27">For analyses of remission and response in the mega-analysis, we applied a Bonferroni multiple testing correction to account for the three outcome measures (primary anxiety remission, all anxiety remission and treatment response), giving a corrected significance level of <italic>P</italic> = 0.016. However, the outcome measures used in this study are highly related and nested within each other, and all analyses presented test the same core hypotheses; thus, the correction is likely conservative.</p>
                  <p id="P28">All analyses were performed in STATA version 11.<sup><xref rid="R30" ref-type="bibr">30</xref></sup></p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results" id="S15">
              <title>Results</title>
              <sec id="S16">
                <title>Remission rates</title>
                <p id="P29">Remission rates are given in <xref ref-type="table" rid="T1">Table 1</xref> and were marginally higher than in previous studies,<sup><xref rid="R3" ref-type="bibr">3</xref></sup> with 61.1% of children remitting from their primary anxiety disorder after treatment, and 71.8% by follow-up. There were no significant differences between remitters and non-remitters for age and gender (age: primary <italic>t</italic>(604) = −0.16, <italic>P</italic> = 0.874; all anxiety <italic>t</italic>(570) = −0.76, <italic>P</italic> = 0.449; gender: primary χ<sup>2</sup><sub>1</sub> = 0.42, <italic>P</italic> = 0.515; all anxiety χ<sup>2</sup><sub>1</sub> = 0.47, <italic>P</italic> = 0.492). Outcome data by genotype are also given in <xref ref-type="table" rid="T1">Table 1</xref> for the additive model, and <xref ref-type="fig" rid="F1">Fig. 1</xref> shows outcomes for the recessive model. Individuals with the SS genotype were 1.7% more likely than those with SL/LL genotype to remit from their primary anxiety diagnosis and 6.5% more likely to remit from all anxiety diagnoses at follow-up. However, differences between the groups were not statistically significant.</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Treatment outcome (response and remission) in Cohort 2 by 5HTTLPR genotype</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1">Treatment outcome</th>
                        <th rowspan="1" colspan="1">Time point</th>
                        <th rowspan="1" colspan="1">Cohort 2</th>
                        <th rowspan="1" colspan="1">SS genotype</th>
                        <th rowspan="1" colspan="1">SL genotype</th>
                        <th rowspan="1" colspan="1">LL genotype</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Primary anxiety disorder remission<sup><xref ref-type="table-fn" rid="TFN2">a</xref></sup></td>
                        <td rowspan="1" colspan="1">Post-treatment</td>
                        <td rowspan="1" colspan="1">61.1</td>
                        <td rowspan="1" colspan="1">63.7</td>
                        <td rowspan="1" colspan="1">59.2</td>
                        <td rowspan="1" colspan="1">62.6</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">Follow-up</td>
                        <td rowspan="1" colspan="1">71.8</td>
                        <td rowspan="1" colspan="1">73.1</td>
                        <td rowspan="1" colspan="1">72.3</td>
                        <td rowspan="1" colspan="1">69.5</td>
                      </tr>
                      <tr>
                        <td colspan="6" rowspan="1">
                          <hr/>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">All anxiety diagnoses remission<sup><xref ref-type="table-fn" rid="TFN2">a</xref></sup></td>
                        <td rowspan="1" colspan="1">Post-treatment</td>
                        <td rowspan="1" colspan="1">42.0</td>
                        <td rowspan="1" colspan="1">40.7</td>
                        <td rowspan="1" colspan="1">42.0</td>
                        <td rowspan="1" colspan="1">43.2</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">Follow-up</td>
                        <td rowspan="1" colspan="1">55.7</td>
                        <td rowspan="1" colspan="1">60.8</td>
                        <td rowspan="1" colspan="1">55.0</td>
                        <td rowspan="1" colspan="1">52.4</td>
                      </tr>
                      <tr>
                        <td colspan="6" rowspan="1">
                          <hr/>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Primary anxiety disorder response<sup><xref ref-type="table-fn" rid="TFN3">b</xref></sup></td>
                        <td rowspan="1" colspan="1">Post-treatment</td>
                        <td rowspan="1" colspan="1">3.39 (2.14)</td>
                        <td rowspan="1" colspan="1">3.47 (2.13)</td>
                        <td rowspan="1" colspan="1">3.29 (2.14)</td>
                        <td rowspan="1" colspan="1">3.52 (2.16)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">Follow-up</td>
                        <td rowspan="1" colspan="1">4.04 (2.21)</td>
                        <td rowspan="1" colspan="1">4.18 (2.16)</td>
                        <td rowspan="1" colspan="1">3.98 (2.21)</td>
                        <td rowspan="1" colspan="1">4.04 (2.24)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="TFN1">
                      <p>Comparisons between genotype groups are not statistically significant for any treatment outcome in Cohort 2.</p>
                    </fn>
                    <fn id="TFN2">
                      <label>a.</label>
                      <p>Values for remission are the percentage free of primary and all anxiety disorder diagnoses at post-treatment and at follow-up.</p>
                    </fn>
                    <fn id="TFN3">
                      <label>b.</label>
                      <p>Values for primary anxiety disorder response are the mean change in severity from the initial assessment at pre-treatment to the time point specified (s.d. in brackets).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig id="F1" orientation="portrait" position="float">
                  <label>Fig. 1</label>
                  <caption>
                    <p>Remission rates and response to cognitive–behavioural therapy (CBT).</p>
                    <p>Figure 1(a) shows the proportion of children free of their primary anxiety disorder and all anxiety diagnoses at follow-up, split by 5HTTLPR genotype in Cohort 2. Figure 1(b) shows the change in primary anxiety symptom severity rating across the course of treatment by 5HTTLPR genotype in Cohort 2. Genotype was not significantly associated with any outcome measure (<italic>P</italic>&gt;0.05 for all analyses). Figure 1(c) shows the proportion of children free of their primary anxiety disorder and all anxiety diagnoses at follow-up, split by 5HTTLPR genotype in the combined sample. Figure 1(d) shows the change in primary anxiety symptom severity rating across the course of treatment by 5HTTLPR genotype in the combined sample. Genotype was not significantly associated with primary anxiety remission or response (<italic>P</italic>&gt;0.05 for all analyses), but those homozygous for the short allele showed a significantly greater remission for all anxiety disorders in the combined sample, even when clinical covariates were taken into account (*OR = 0.45, <italic>P</italic> = 0.014).</p>
                  </caption>
                  <graphic xlink:href="185f1"/>
                </fig>
              </sec>
              <sec id="S17">
                <title>Logistic mixed effects models – predicting remission</title>
                <p id="P30">No significant effect of genotype on treatment outcome was detected for either primary or all anxiety diagnoses at post-treatment (<xref ref-type="table" rid="T2">Table 2</xref>; primary: OR = 0.92, <italic>P</italic> = 0.551; all anxiety: OR = 1.09, <italic>P</italic> = 0.607); or at follow-up (<xref ref-type="table" rid="T2">Table 2</xref>; primary: OR = 0.83, <italic>P</italic>= 0.318; all anxiety: OR = 0.66, <italic>P</italic> = 0.293). The odds ratio of less than 1 indicates that, as found previously, participants with the SS genotype were more likely to remit than SL/LL children. A similar pattern of effects was seen when analyses were restricted to the White European subset (see Table DS1 in the online data supplement).</p>
                <table-wrap id="T2" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Mixed effect models; categorical remission and change in symptom severity at post-treatment and follow-up for primary anxiety diagnosis; remission from all anxiety disorder diagnoses at post-treatment and follow-up</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="right" valign="middle" span="1"/>
                      <col align="right" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th colspan="6" rowspan="1">Remission<hr/></th>
                        <th colspan="3" rowspan="1">Response – change in CSR<hr/></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th colspan="3" rowspan="1">Primary anxiety disorder (<italic>n</italic> = 792)<hr/></th>
                        <th colspan="3" rowspan="1">All anxiety diagnoses (<italic>n</italic> = 747)<hr/></th>
                        <th colspan="3" rowspan="1">Primary anxiety disorder (<italic>n</italic> = 788)<hr/></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">Time point</th>
                        <th rowspan="1" colspan="1">OR</th>
                        <th rowspan="1" colspan="1">95% CI</th>
                        <th rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                        <th rowspan="1" colspan="1">OR</th>
                        <th rowspan="1" colspan="1">95% CI</th>
                        <th rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                        <th align="center" rowspan="1" colspan="1">β</th>
                        <th align="center" rowspan="1" colspan="1">95% CI</th>
                        <th rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Post-treatment</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Genotype</td>
                        <td rowspan="1" colspan="1">0.92</td>
                        <td rowspan="1" colspan="1">0.71 to 1.20</td>
                        <td rowspan="1" colspan="1">0.551</td>
                        <td rowspan="1" colspan="1">1.09</td>
                        <td rowspan="1" colspan="1">0.79 to 1.48</td>
                        <td rowspan="1" colspan="1">0.607</td>
                        <td rowspan="1" colspan="1">−0.04</td>
                        <td rowspan="1" colspan="1">−0.11 to 0.03</td>
                        <td rowspan="1" colspan="1">0.294</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Time</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">−1.36</td>
                        <td rowspan="1" colspan="1">−1.41 to 1.30</td>
                        <td rowspan="1" colspan="1">0.000</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Baseline severity</td>
                        <td rowspan="1" colspan="1">1.15</td>
                        <td rowspan="1" colspan="1">1.03 to 1.29</td>
                        <td rowspan="1" colspan="1">0.013</td>
                        <td rowspan="1" colspan="1">1.22</td>
                        <td rowspan="1" colspan="1">1.07 to 1.39</td>
                        <td rowspan="1" colspan="1">0.003</td>
                        <td rowspan="1" colspan="1">0.29</td>
                        <td rowspan="1" colspan="1">0.26 to 0.32</td>
                        <td rowspan="1" colspan="1">0.000</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Age</td>
                        <td rowspan="1" colspan="1">1.02</td>
                        <td rowspan="1" colspan="1">0.97 to 1.08</td>
                        <td rowspan="1" colspan="1">0.367</td>
                        <td rowspan="1" colspan="1">1.00</td>
                        <td rowspan="1" colspan="1">0.94 to 1.07</td>
                        <td rowspan="1" colspan="1">0.936</td>
                        <td rowspan="1" colspan="1">0.01</td>
                        <td rowspan="1" colspan="1">−0.00 to 0.03</td>
                        <td rowspan="1" colspan="1">0.083</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Gender</td>
                        <td rowspan="1" colspan="1">1.07</td>
                        <td rowspan="1" colspan="1">0.86 to 1.33</td>
                        <td rowspan="1" colspan="1">0.539</td>
                        <td rowspan="1" colspan="1">1.25</td>
                        <td rowspan="1" colspan="1">0.97 to 1.62</td>
                        <td rowspan="1" colspan="1">0.088</td>
                        <td rowspan="1" colspan="1">0.03</td>
                        <td rowspan="1" colspan="1">−0.03 to 0.09</td>
                        <td rowspan="1" colspan="1">0.279</td>
                      </tr>
                    </tbody>
                  </table>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="right" valign="middle" span="1"/>
                      <col align="right" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th colspan="3" rowspan="1">Primary anxiety disorder (<italic>n</italic> = 606)<hr/></th>
                        <th colspan="3" rowspan="1">All anxiety diagnoses (<italic>n</italic> = 573)<hr/></th>
                        <th colspan="3" rowspan="1">Primary anxiety disorder (<italic>n</italic> = 581)<hr/></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">Time point</th>
                        <th rowspan="1" colspan="1">OR</th>
                        <th rowspan="1" colspan="1">95% CI</th>
                        <th rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                        <th rowspan="1" colspan="1">OR</th>
                        <th rowspan="1" colspan="1">95% CI</th>
                        <th rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                        <th align="center" rowspan="1" colspan="1">β</th>
                        <th align="center" rowspan="1" colspan="1">95% CI</th>
                        <th rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Follow-up</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Genotype</td>
                        <td rowspan="1" colspan="1">0.83</td>
                        <td rowspan="1" colspan="1">0.35 to 1.99</td>
                        <td rowspan="1" colspan="1">0.679</td>
                        <td rowspan="1" colspan="1">0.66</td>
                        <td rowspan="1" colspan="1">0.31 to 1.43</td>
                        <td rowspan="1" colspan="1">0.293</td>
                        <td rowspan="1" colspan="1">−0.04</td>
                        <td rowspan="1" colspan="1">−0.13 to 0.04</td>
                        <td rowspan="1" colspan="1">0.318</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Time</td>
                        <td rowspan="1" colspan="1">0.00</td>
                        <td rowspan="1" colspan="1">0.00 to 0.01</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">0.00</td>
                        <td rowspan="1" colspan="1">0.00 to 0.02</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">−1.03</td>
                        <td rowspan="1" colspan="1">−1.09 to 0.97</td>
                        <td rowspan="1" colspan="1">0.000</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Time<sup>2</sup></td>
                        <td rowspan="1" colspan="1">2.72</td>
                        <td rowspan="1" colspan="1">1.76 to 4.19</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">2.27</td>
                        <td rowspan="1" colspan="1">1.64 to 3.13</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">0.15</td>
                        <td rowspan="1" colspan="1">0.13 to 0.16</td>
                        <td rowspan="1" colspan="1">0.000</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Baseline severity</td>
                        <td rowspan="1" colspan="1">2.05</td>
                        <td rowspan="1" colspan="1">1.31 to 3.21</td>
                        <td rowspan="1" colspan="1">0.002</td>
                        <td rowspan="1" colspan="1">1.99</td>
                        <td rowspan="1" colspan="1">1.36 to 2.93</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">0.27</td>
                        <td rowspan="1" colspan="1">0.23 to 0.30</td>
                        <td rowspan="1" colspan="1">0.000</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Age</td>
                        <td rowspan="1" colspan="1">0.96</td>
                        <td rowspan="1" colspan="1">0.80 to 1.14</td>
                        <td rowspan="1" colspan="1">0.631</td>
                        <td rowspan="1" colspan="1">1.02</td>
                        <td rowspan="1" colspan="1">0.88 to 1.20</td>
                        <td rowspan="1" colspan="1">0.750</td>
                        <td rowspan="1" colspan="1">0.00</td>
                        <td rowspan="1" colspan="1">−0.02 to 0.02</td>
                        <td rowspan="1" colspan="1">0.957</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">    Gender</td>
                        <td rowspan="1" colspan="1">0.79</td>
                        <td rowspan="1" colspan="1">0.39 to 1.62</td>
                        <td rowspan="1" colspan="1">0.523</td>
                        <td rowspan="1" colspan="1">1.20</td>
                        <td rowspan="1" colspan="1">0.64 to 2.23</td>
                        <td rowspan="1" colspan="1">0.569</td>
                        <td rowspan="1" colspan="1">0.03</td>
                        <td rowspan="1" colspan="1">−0.04 to 0.10</td>
                        <td rowspan="1" colspan="1">0.461</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="TFN4">
                      <p>CSR, clinical severity rating.</p>
                    </fn>
                    <fn id="TFN5">
                      <p>5HTTLPR genotype is defined using a recessive model, where SS = 1 and LL/LS = 0. Age and baseline severity are centered at the mean.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="S18">
                <title>Change in symptom severity</title>
                <p id="P31">Mean primary anxiety disorder severity at pre-treatment was 6.20 (s.d. = 1.05). At post-treatment, mean severity was 2.82 (s.d. = 2.12), corresponding with a change from pre-treatment of 3.39 (s.d. = 2.14; <xref ref-type="table" rid="T1">Table 1</xref>). Mean severity at follow-up was 2.15 (s.d. = 2.17) with a mean change from pre-treatment of 4.04 (s.d. = 2.21). There were no significant effects of age or gender on change in symptom severity in Cohort 2 (age: β = −0.01, <italic>P</italic> = 0.55; gender: β = 0.04, <italic>P</italic>= 0.53). Change in severity by genotype is shown in <xref ref-type="table" rid="T1">Table 1</xref> and <xref ref-type="fig" rid="F1">Fig. 1(b)</xref>. Participants with SS genotype showed a marginally greater reduction in symptom severity by post-treatment (0.10) and by follow-up (0.18) than SL/LL genotype carriers but differences between the groups were not significant.</p>
              </sec>
              <sec id="S19">
                <title>Linear mixed effects models – predicting response</title>
                <p id="P32">No significant effect of genotype on change in primary diagnosis symptom severity was detected, either during the course of treatment (<xref ref-type="table" rid="T2">Table 2</xref>; pre-treatment to post-treatment: β = −0.04, <italic>P</italic> = 0.294) or at follow-up (pre-treatment to follow-up: β = −0.04, <italic>P</italic> = 0.318). This was also true of the White European subset (online Table DS1). The overall standardised beta coefficient of −0.04 indicates that SS children had a 0.04 s.d. greater reduction in severity scores than SL/LL children.</p>
              </sec>
              <sec id="S20">
                <title>Mega-analyses</title>
                <p id="P33">Before combining Cohorts 1 and 2 for analyses, the two cohorts were compared for key variables. There were no significant differences in gender distribution (χ<sup>2</sup><sub>1</sub> = 2.39, <italic>P</italic> = 0.122), treatment modality (χ<sup>2</sup><sub>2</sub> = 4.07, <italic>P</italic> = 0.131) or recessive genotype (χ<sup>2</sup><sub>1</sub> = 1.98, <italic>P</italic> = 0.159). Due to the recruitment from additional studies in Cohort 2, a larger age range was included and Cohort 2 was significantly older (<italic>t</italic>(1271) = 5.15, <italic>P</italic> = 0.0001). Cohort 2 also showed significantly higher rates of remission at post-treatment (primary: χ<sup>2</sup><sub>1</sub> = 7.72, <italic>P</italic> = 0.005; all anxiety: χ<sup>2</sup><sub>1</sub> = 7.35, <italic>P</italic> = 0.007) and at follow-up (primary: χ<sup>2</sup><sub>1</sub> = 7.24, <italic>P</italic> = 0.007; all anxiety: χ<sup>2</sup><sub>1</sub> = 13.60, <italic>P</italic> = 0.000).</p>
                <p id="P34">In the entire sample (Cohorts 1 and 2 combined), SS participants were 6.6% more likely to remit from their primary anxiety disorder, and 11.4% more likely to remit from all anxiety disorder diagnoses than SL/LL carriers (<xref ref-type="fig" rid="F1">Fig. 1(c)</xref>). Additionally, SS carriers showed a greater reduction in symptom severity from pre-treatment to follow-up than SL/LL carriers (<xref ref-type="fig" rid="F1">Fig. 1(d)</xref>; SS: change = 4.01, s.d. = 2.05; SL/LL: change = 3.79, s.d. = 2.19).</p>
                <p id="P35">When using linear and logistic mixed effect models, the effect of genotype on primary anxiety disorder response and remission did not reach statistical significance (<xref ref-type="table" rid="T3">Table 3</xref>; change in CSR: β = −0.06, <italic>P</italic> = 0.070; remission: OR = 0.55, <italic>P</italic> = 0.095). However, there was a significant effect of genotype on all anxiety diagnoses remission (<xref ref-type="table" rid="T3">Table 3</xref>; OR = 0.45, <italic>P</italic> = 0.014), which remained nominally significant when multiple testing corrections were made. In the White European subset, a similar pattern of results was detected, although these did not reach statistical significance (see online Table DS2).</p>
                <table-wrap id="T3" orientation="portrait" position="float">
                  <label>Table 3</label>
                  <caption>
                    <p>Mega-analyses; results combining Cohorts 1 and 2. Outcome measures; primary anxiety disorder remission at follow-up, change in primary anxiety CSR from pre-treatment to follow-up, all anxiety disorder diagnoses remission at follow-up</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                      <col align="right" valign="middle" span="1"/>
                      <col align="right" valign="middle" span="1"/>
                      <col align="center" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th colspan="6" rowspan="1">Remission<hr/></th>
                        <th colspan="3" rowspan="1">Response – change in CSR<hr/></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th colspan="3" rowspan="1">Primary anxiety disorder (<italic>n</italic> =1044)<hr/></th>
                        <th colspan="3" rowspan="1">All anxiety diagnoses (<italic>n</italic> = 1011)<hr/></th>
                        <th colspan="3" rowspan="1">Primary anxiety disorder (<italic>n</italic> = 1019)<hr/></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">Predictor variable at follow-up</th>
                        <th rowspan="1" colspan="1">OR</th>
                        <th rowspan="1" colspan="1">95% CI</th>
                        <th rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                        <th rowspan="1" colspan="1">OR</th>
                        <th rowspan="1" colspan="1">95% CI</th>
                        <th rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                        <th align="center" rowspan="1" colspan="1">β</th>
                        <th align="center" rowspan="1" colspan="1">95% CI</th>
                        <th rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Genotype</td>
                        <td rowspan="1" colspan="1">0.55</td>
                        <td rowspan="1" colspan="1">0.27 to 1.11</td>
                        <td rowspan="1" colspan="1">0.095</td>
                        <td rowspan="1" colspan="1">0.45</td>
                        <td rowspan="1" colspan="1">0.25 to 0.88</td>
                        <td rowspan="1" colspan="1">
                          <bold>0.014</bold>
                        </td>
                        <td rowspan="1" colspan="1">−0.06</td>
                        <td rowspan="1" colspan="1">−0.13 to 0.01</td>
                        <td rowspan="1" colspan="1">0.070</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Time</td>
                        <td rowspan="1" colspan="1">0.00</td>
                        <td rowspan="1" colspan="1">0.00 to 0.01</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">0.00</td>
                        <td rowspan="1" colspan="1">0.00 to 0.01</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">−0.91</td>
                        <td rowspan="1" colspan="1">−0.95 to 0.86</td>
                        <td rowspan="1" colspan="1">0.000</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Time<sup>2</sup></td>
                        <td rowspan="1" colspan="1">2.55</td>
                        <td rowspan="1" colspan="1">1.94 to 3.36</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">2.17</td>
                        <td rowspan="1" colspan="1">1.73 to 2.72</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">0.13</td>
                        <td rowspan="1" colspan="1">0.11 to 0.14</td>
                        <td rowspan="1" colspan="1">0.000</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline severity</td>
                        <td rowspan="1" colspan="1">2.05</td>
                        <td rowspan="1" colspan="1">1.44 to 2.91</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">2.30</td>
                        <td rowspan="1" colspan="1">1.63 to 3.23</td>
                        <td rowspan="1" colspan="1">0.000</td>
                        <td rowspan="1" colspan="1">0.27</td>
                        <td rowspan="1" colspan="1">0.24 to 0.29</td>
                        <td rowspan="1" colspan="1">0.000</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Age</td>
                        <td rowspan="1" colspan="1">0.95</td>
                        <td rowspan="1" colspan="1">0.83 to 1.10</td>
                        <td rowspan="1" colspan="1">0.497</td>
                        <td rowspan="1" colspan="1">0.99</td>
                        <td rowspan="1" colspan="1">0.87 to 1.12</td>
                        <td rowspan="1" colspan="1">0.833</td>
                        <td rowspan="1" colspan="1">−0.01</td>
                        <td rowspan="1" colspan="1">−0.02 to 0.01</td>
                        <td rowspan="1" colspan="1">0.360</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Gender</td>
                        <td rowspan="1" colspan="1">1.21</td>
                        <td rowspan="1" colspan="1">0.70 to 2.09</td>
                        <td rowspan="1" colspan="1">0.502</td>
                        <td rowspan="1" colspan="1">1.33</td>
                        <td rowspan="1" colspan="1">0.81 to 2.20</td>
                        <td rowspan="1" colspan="1">0.257</td>
                        <td rowspan="1" colspan="1">0.05</td>
                        <td rowspan="1" colspan="1">−0.00 to 0.10</td>
                        <td rowspan="1" colspan="1">0.070</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Cohort</td>
                        <td rowspan="1" colspan="1">0.65</td>
                        <td rowspan="1" colspan="1">0.33 to 1.27</td>
                        <td rowspan="1" colspan="1">0.206</td>
                        <td rowspan="1" colspan="1">0.55</td>
                        <td rowspan="1" colspan="1">0.30 to 1.02</td>
                        <td rowspan="1" colspan="1">0.056</td>
                        <td rowspan="1" colspan="1">−0.05</td>
                        <td rowspan="1" colspan="1">−0.12 to 0.01</td>
                        <td rowspan="1" colspan="1">0.100</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="TFN6">
                      <p>CSR, clinical severity rating.</p>
                    </fn>
                    <fn id="TFN7">
                      <p>5HTTLPR genotype is defined using a recessive model, where SS = 1 and LL/LS = 0. Age and baseline severity are centred at the mean. Statistically significant results for genotype are highlighted.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="discussion" id="S21">
              <title>Discussion</title>
              <p id="P36">We attempted to replicate our previously reported association between 5HTTLPR genotype and outcome following CBT. Our replication sample comprised 829 children with a primary anxiety diagnosis. We found no significant association between genotype and remission of primary or all anxiety diagnoses at post-treatment or follow-up time-points. Furthermore, change in primary anxiety disorder symptom severity (response) across the course of treatment did not differ as a function of 5HTTLPR genotype. Mega-analyses combining data from this and our previous report<sup><xref rid="R15" ref-type="bibr">15</xref></sup> revealed a significant association between 5HTTLPR genotype and remission of all anxiety disorders at follow-up. Children carrying the SS genotype were more likely to be free of all anxiety disorder diagnoses than children with the SL/LL genotype. This effect remained significant after multiple testing corrections.</p>
              <p id="P37">In our previous paper, 20% (18.8%) more children with the SS compared with SL/LL genotypes were free of their primary (all) anxiety disorders at follow-up.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> The odds ratios were 0.39 (0.44) for primary (all) anxiety remission. In this study, the effects observed were in the same direction but were markedly smaller and non-significant. This overestimation of effect size within discovery samples is often, at least in part, responsible for the failure of subsequent studies to replicate genetic effects. This is because replication studies are usually underpowered. This study far exceeded the required <italic>N</italic> of 285 needed to detect an effect of OR = 0.39 (as observed in our previous study) with 80% power and α = 0.01. With a sample size of at least 600 in each analysis, this study was sufficiently powered to detect an OR = 0.39 with greater than 99% power and α = 0.001. However, if the true effect of 5HTTLPR in predicting CBT response is closer to the 0.66 observed in the present study, then this would require a sample of <italic>N</italic>&gt;900 to detect this effect at α = 0.01 with 80% power (taking into account the higher remission rate in the Cohort 2).</p>
              <p id="P38">Mega-analyses are one means of increasing statistical power. To this end, we examined the overall effect of 5HTTLPR genotype on CBT outcome using all data available from this and our previous paper. This allowed us to increase the available sample size to <italic>n</italic> = 1044. The effect of genotype on change in primary anxiety disorder symptom severity was suggestive of an improved response for SS genotype carriers but did not reach conventional levels of significance. We found weak evidence of an association between 5HTTLPR genotype and remission of all anxiety diagnoses at follow-up, which was consistent with our previous findings.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> SS genotype carriers were half as likely as SL/LL carriers to retain any anxiety disorder diagnosis at follow-up (OR = 0.45). The odds ratio for primary anxiety disorder remission was in the same direction (OR = 0.55) but did not attain statistical significance. These findings suggest that the 5HTTLPR genotype accounts for only a very small amount of the variance in outcome following CBT. Importantly, the 95% confidence intervals around the OR of 0.45 (for all anxiety disorder remission) suggest that the true effect size lies somewhere between 0.25 and 0.88 and thus effectively provides an upper bound for estimating the effect of 5HTTLPR on remission following CBT. However, given the tendency of early candidate gene discoveries to overestimate the true effect, it remains highly plausible that the true effect may in fact be nearer the lower bound estimate of 0.88 (a higher value represents a smaller effect size with respect to these analyses; see results section for further details). Future research attempting to investigate outcome following psychological treatments as a function of 5HTTLPR genotype should use this information when making decisions regarding appropriate sample size.</p>
              <p id="P39">The current paper adds to the expanding therapygenetics literature investigating the 5HTTLPR polymorphism.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Although this marker is a plausible candidate for involvement in outcome following psychological therapy, 8 out of 11 studies have failed to find a significant association between the 5HTTLPR and treatment response, with the present study being by far the most highly powered. The remaining studies observed mixed effects: two studies<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> found a significant association between the SS genotype and a more positive treatment response, which is consistent with the mega-analyses reported herein. However, a third small study<sup><xref rid="R18" ref-type="bibr">18</xref></sup> reported the opposite with the SS genotype associated with fewer treatment gains. The weak and contradictory findings seen thus far may reflect varying disorder and treatment response phenotypes, the role of medication in some studies and small, underpowered sample sizes.<sup><xref rid="R14" ref-type="bibr">14</xref></sup></p>
              <p id="P40">The use of a semi-structured diagnostic instrument to characterise treatment outcome and agreement across study sites on the definition of response are significant strengths of this study. This study is also the largest to date to investigate genetic predictors of outcome following psychological therapy. However, there are some limitations. First, the sample is very heterogeneous, including a range of anxiety diagnoses and several different CBT modalities. One possibility is that the 5HTTLPR may have greater predictive power when the sample and treatment is more homogeneous.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Second, the current study takes a candidate gene approach. In all areas of psychiatric genetics, candidate gene studies typically report very small effect sizes, often fail to replicate and are sensitive to publication bias.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> To be able to nominate candidate genes for investigation also requires a clear understanding of the pathophysiology of the phenotype under investigation and the putative mechanisms through which psychological therapies may act. We know that psychological treatment response is a complex trait, thus it is very unlikely that a single genetic polymorphism such as the 5HTTLPR will explain a sufficiently large amount of variance in outcome to be clinically meaningful in its own right. Although there remains a place for adequately powered studies of plausible candidate genes within the therapygenetics field, this challenge means it will become increasingly important to move towards a whole-genome array-based ‘therapygenomics’ approach. Whole-genome studies are hypothesis free and thus have the potential to identify completely novel and unexpected variants associated with psychological treatment response. Perhaps, most importantly, there is the ability to move beyond single variants and to identify groups of markers and important biological pathways and systems, which collectively capture a (clinically) significant proportion of the variance in outcome. However, it is important to note that some genetic variants (including the 5HTTLPR) cannot be adequately inferred from array data and will continue to need to be genotyped directly. Given the importance of clinical and demographic predictors,<sup><xref rid="R24" ref-type="bibr">24</xref></sup> optimal prediction of CBT response is likely to come from analytic approaches, which aggregate genetic information with clinical and demographic variables.<sup><xref rid="R33" ref-type="bibr">33</xref></sup></p>
              <p id="P41">In summary, this study failed to replicate our previously reported association between 5HTTLPR genotype and outcome following CBT for child anxiety disorders. Consistent with our previous findings SS genotype carriers had a more positive treatment response compared with SL/LL genotype carriers. However, these effects were very small and mostly non-significant. The increased sample size afforded by a mega-analytic approach revealed a significant association between SS genotype and remission of all anxiety disorders, which survived multiple testing corrections. Importantly, this work provides an upper and lower bound for estimating the effect size of association between 5HTTLPR and CBT outcomes, which are informative for other researchers working in this area. Going forward, the therapy-genetics field needs to embrace whole genome approaches and to look to recruit large, homogenous samples in which to explore genetic predictors of outcome following psychological therapies.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="conflict">
                <p>
                  <bold>Declaration of interest</bold>
                </p>
                <p>R.M.R., J.L.H. and H.J.L. are authors of the Cool Kids programme, but receive no direct payments. C.C. was joint author of a book used in treatment within the Overcoming trial and P.W. was joint editor for a book on the treatment of obsessive–compulsive disorder and they receive royalties from sales of the books. W.K.S. is an author of the Anxiety Disorders Interview Schedule for Children from which she receives royalties.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p>
                  <bold>Funding</bold>
                </p>
                <p>Combined study supported by UK <funding-source>Medical Research Council</funding-source> grant <award-id specific-use="grant">G0901874/1</award-id> to Eley. Lester supported by <funding-source>UK Medical Research Council</funding-source> grant (<award-id specific-use="grant">MR/J011762/1</award-id>) and <funding-source>Jacobs Foundation Young Scholar</funding-source> grant. Keers supported by <funding-source>UK Medical Research Council Population Health fellowship</funding-source> (<award-id specific-use="grant">MR/K021281/1</award-id>). Individual trials support by <funding-source>Australian Research Council</funding-source> grant <award-id specific-use="grant">DP0878609</award-id> to Hudson, Rapee, and Eley; <funding-source>Australian NHMRC</funding-source> grants to Rapee, Hudson, Lyneham, Mihalopolous (<award-id specific-use="grant">1027556</award-id>), Lyneham, Hudson and Rapee (<award-id specific-use="grant">488505</award-id>) and Hudson and Rapee (<award-id specific-use="grant">382008</award-id>); <funding-source>TrygFonden</funding-source> grant (<award-id specific-use="grant">7-10-1391</award-id>) to Thastum &amp; Esben Hougaard; <funding-source>Edith ogGodtfred Kirk Christiansens Fond</funding-source> grant (<award-id specific-use="grant">21-5675</award-id>) to Thastum; <funding-source>Swiss National Science Foundation</funding-source> grant (<award-id specific-use="grant">105314-116517</award-id>) to Schneider, <funding-source>Western Norway Regional Health Authority</funding-source> grants to Odd Havik (<award-id specific-use="grant">911253</award-id>) and Heiervang (<award-id specific-use="grant">911366</award-id>); <funding-source>UK Medical Research Council Clinical Fellowship</funding-source> (<award-id specific-use="grant">G0802821</award-id>) to Richard Meiser-Stedman; <funding-source>NIMH R01</funding-source> (<award-id specific-use="grant">MH079943</award-id>) to Silverman; <funding-source>UK NIHR</funding-source> grants to Creswell (<award-id specific-use="grant">PB-PG-0110-21190</award-id>) and Cooper (<award-id specific-use="grant">PB-PG-0107-12042</award-id>); <funding-source>UK Medical Research Council</funding-source> Grants to Cooper and Creswell (<award-id specific-use="grant">09-800-17</award-id>), Thirlwall, Cooper and Creswell (<award-id specific-use="grant">G0802326</award-id>), Waite, Creswell and Cooper (<award-id specific-use="grant">G1002011</award-id>), and Creswell (<award-id specific-use="grant">G0601874</award-id>). Grant 09/800/17 was managed by NIHR on behalf of the <funding-source>MRC-NIHR</funding-source> partnership. <funding-source>UK NIHR</funding-source> grants to Creswell, Cooper, Emma McIntosh &amp; Lucy Willetts (<award-id specific-use="grant">PB-PG-0110-21190</award-id>) and Cooper, Creswell, Lucy Willetts &amp; Paul Sheffied (<award-id specific-use="grant">PB-PG-0107-12042</award-id>); This study presents independent research part-funded by the <funding-source>National Institute for Health Research (NIHR)</funding-source>
<funding-source>Biomedical Research Centre at South London</funding-source> and <funding-source>Maudsley NHS Foundation Trust</funding-source> and <funding-source>King's College London</funding-source>. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.</p>
              </fn>
            </fn-group>
            <ack>
              <p id="P42">We thank Irma Knuistingh Neven, Marianne Bjerregaard Madsen, Lisbeth Jørgensen, Carmen Adornetto, Kristine Fonnes Griffin, Elisa Kulewski, Jonas Großekathöfer, Nora Dirks, Evelyn Kmelnitski, Sabrina Heuser, Adrian Boyle, Clare Dixon, Harma Moorlag, Nienke Boersma, Sue Cruddace, Marie Weber, Zoe Hughes, Kiri Clarke, Francoise Hentges, Liz White, Nynke Wagenaar, Luci Motoca, Yesenia Rodriguez, Klaudia Perreira, Erin Hedemann, Cristina Del Busto, Gillian O'Neill, Lucy Lindley, Rachel Banham, Nora Delvendahl, HjaltiJonsson, Kristen Lavallee, Tina In-Albon, Odd E. Havik, Krister Fjermestad, Katrin Hötzel, Richard Meiser-Stedman, Tim Dalgleish, and Carla Marin for their contributions.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Berglund</surname><given-names>P</given-names></name><name><surname>Demler</surname><given-names>O</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Merikangas</surname><given-names>KR</given-names></name><name><surname>Walters</surname><given-names>EE</given-names></name></person-group><article-title>Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication</article-title>. <source>Arch Gen Psychiatry</source><year>2005</year>; <volume>62</volume>: <fpage>593</fpage>–<lpage>602</lpage>.
<pub-id pub-id-type="pmid">15939837</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bittner</surname><given-names>A</given-names></name><name><surname>Egger</surname><given-names>HL</given-names></name><name><surname>Erkanli</surname><given-names>A</given-names></name><name><surname>Jane Costello</surname><given-names>E</given-names></name><name><surname>Foley</surname><given-names>DL</given-names></name><name><surname>Angold</surname><given-names>A</given-names></name></person-group><article-title>What do childhood anxiety disorders predict?</article-title><source>J Child Psychol Psychiatry</source><year>2007</year>; <volume>48</volume>: <fpage>1174</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="pmid">18093022</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>AC</given-names></name><name><surname>James</surname><given-names>G</given-names></name><name><surname>Cowdrey</surname><given-names>F</given-names></name><name><surname>Soler</surname><given-names>A</given-names></name><name><surname>Choke</surname><given-names>A</given-names></name></person-group><article-title>Cognitive behavioural therapy for anxiety disorders in children and adolescents</article-title>. <source>Cochrane Database Syst Rev</source><year>2013</year>; <volume>6</volume>: <comment>CD004690</comment>.
</mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesch</surname><given-names>K-P</given-names></name><name><surname>Bengel</surname><given-names>D</given-names></name><name><surname>Heils</surname><given-names>A</given-names></name><name><surname>Sabol</surname><given-names>SZ</given-names></name><name><surname>Greenberg</surname><given-names>BD</given-names></name><name><surname>Petri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region</article-title>. <source>Science</source><year>1996</year>; <volume>274</volume>: <fpage>1527</fpage>–<lpage>31</lpage>.
<pub-id pub-id-type="pmid">8929413</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Burmeister</surname><given-names>M</given-names></name><name><surname>Ghosh</surname><given-names>D</given-names></name></person-group><article-title>Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits</article-title>. <source>Am J Med Genet B Neuropsychiatr Genet</source><year>2004</year>; <volume>127B</volume>: <fpage>85</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="pmid">15108187</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munafò</surname><given-names>MR</given-names></name><name><surname>Freimer</surname><given-names>NB</given-names></name><name><surname>Ng</surname><given-names>W</given-names></name><name><surname>Ophoff</surname><given-names>R</given-names></name><name><surname>Veijola</surname><given-names>J</given-names></name><name><surname>Miettunen</surname><given-names>J</given-names></name><etal/></person-group><article-title>5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data</article-title>. <source>Am J Med Genet B Neuropsychiatr Genet</source><year>2009</year>; <volume>150B</volume>: <fpage>271</fpage>–<lpage>81</lpage>.
<pub-id pub-id-type="pmid">18546120</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karg</surname><given-names>K</given-names></name><name><surname>Burmeister</surname><given-names>M</given-names></name><name><surname>Shedden</surname><given-names>K</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name></person-group><article-title>The serotonin transporter promoter variant (5-httlpr), stress, and depression meta-analysis revisited: evidence of genetic moderation</article-title>. <source>Arch Gen Psychiatry</source><year>2011</year>; <volume>68</volume>: <fpage>444</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="pmid">21199959</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eley</surname><given-names>TC</given-names></name><name><surname>Sugden</surname><given-names>K</given-names></name><name><surname>Corsico</surname><given-names>A</given-names></name><name><surname>Gregory</surname><given-names>AM</given-names></name><name><surname>Sham</surname><given-names>P</given-names></name><name><surname>McGuffin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gene-environment interaction analysis of serotonin system markers with adolescent depression</article-title>. <source>Mol Psychiatry</source><year>2004</year>; <volume>9</volume>: <fpage>908</fpage>–<lpage>15</lpage>.
<pub-id pub-id-type="pmid">15241435</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SE</given-names></name><name><surname>Way</surname><given-names>BM</given-names></name><name><surname>Welch</surname><given-names>WT</given-names></name><name><surname>Hilmert</surname><given-names>CJ</given-names></name><name><surname>Lehman</surname><given-names>BJ</given-names></name><name><surname>Eisenberger</surname><given-names>NI</given-names></name></person-group><article-title>Early family environment, current adversity, the serotonin transporter promoter polymorphism, and depressive symptomatology</article-title>. <source>Biol Psychiatry</source><year>2006</year>; <volume>60</volume>: <fpage>671</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="pmid">16934775</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>K</given-names></name><name><surname>Mitchell</surname><given-names>PB</given-names></name><name><surname>Niven</surname><given-names>H</given-names></name><name><surname>Finch</surname><given-names>A</given-names></name><name><surname>Wedgwood</surname><given-names>L</given-names></name><name><surname>Scimone</surname><given-names>A</given-names></name><etal/></person-group><article-title>Life events, first depression onset and the serotonin transporter gene</article-title>. <source>Br J Psychiatry</source><year>2006</year>; <volume>188</volume>: <fpage>210</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="pmid">16507960</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>MB</given-names></name><name><surname>Campbell-Sills</surname><given-names>L</given-names></name><name><surname>Gelernter</surname><given-names>J</given-names></name></person-group><article-title>Genetic variation in 5HTTLPR is associated with emotional resilience</article-title>. <source>Am J Med Genet B Neuropsychiatr Genet</source><year>2009</year>; <volume>150B</volume>: <fpage>900</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="pmid">19152387</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belsky</surname><given-names>J</given-names></name><name><surname>Jonassaint</surname><given-names>C</given-names></name><name><surname>Pluess</surname><given-names>M</given-names></name><name><surname>Stanton</surname><given-names>M</given-names></name><name><surname>Brummett</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name></person-group><article-title>Vulnerability genes or plasticity genes</article-title>. <source>Mol Psychiatry</source><year>2009</year>; <volume>14</volume>: <fpage>746</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="pmid">19455150</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hankin</surname><given-names>B</given-names></name><name><surname>Nederhof</surname><given-names>E</given-names></name><name><surname>Oppenheimer</surname><given-names>C</given-names></name><name><surname>Jenness</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Abela</surname><given-names>J</given-names></name><etal/></person-group><article-title>Differential susceptibility in youth: evidence that 5-HTTLPR x positive parenting is associated with positive affect “for better and worse”</article-title>. <source>Transl Psychiatry</source><year>2011</year>; <volume>1</volume>: <fpage>e44</fpage>.
<pub-id pub-id-type="pmid">22833190</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lester</surname><given-names>KJ</given-names></name><name><surname>Eley</surname><given-names>TC</given-names></name></person-group><article-title>Therapygenetics: using genetic markers to predict response to psychological treatment for mood and anxiety disorders</article-title>. <source>Biol Mood Anxiety Disord</source><year>2013</year>; <volume>3</volume>: <fpage>1</fpage>–<lpage>16</lpage>.
<pub-id pub-id-type="pmid">23276307</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eley</surname><given-names>TC</given-names></name><name><surname>Hudson</surname><given-names>JL</given-names></name><name><surname>Creswell</surname><given-names>C</given-names></name><name><surname>Tropeano</surname><given-names>M</given-names></name><name><surname>Lester</surname><given-names>KJ</given-names></name><name><surname>Cooper</surname><given-names>P</given-names></name><etal/></person-group><article-title>Therapygenetics: the 5HTTLPR and response to psychological therapy</article-title>. <source>Mol Psychiatry</source><year>2012</year>; <volume>17</volume>: <fpage>236</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="pmid">22024766</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohen</surname><given-names>R</given-names></name><name><surname>Cain</surname><given-names>KC</given-names></name><name><surname>Buzaitis</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>V</given-names></name><name><surname>Becker</surname><given-names>KJ</given-names></name><name><surname>Teri</surname><given-names>L</given-names></name><etal/></person-group><article-title>Response to psychosocial treatment in poststroke depression is associated with serotonin transporter polymorphisms</article-title>. <source>Stroke</source><year>2011</year>; <volume>42</volume>: <fpage>2068</fpage>–<lpage>70</lpage>.
<pub-id pub-id-type="pmid">21847802</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bockting</surname><given-names>CL</given-names></name><name><surname>Mocking</surname><given-names>RJ</given-names></name><name><surname>Lok</surname><given-names>A</given-names></name><name><surname>Koeter</surname><given-names>MW</given-names></name><name><surname>Schene</surname><given-names>AH</given-names></name></person-group><article-title>Therapygenetics: the 5HTTLPR as a biomarker for response to psychological therapy?</article-title><source>Mol Psychiatry</source><year>2012</year>; <volume>18</volume>: <fpage>744</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="pmid">22751490</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>R</given-names></name><name><surname>Felmingham</surname><given-names>K</given-names></name><name><surname>Falconer</surname><given-names>E</given-names></name><name><surname>Benito</surname><given-names>L</given-names></name><name><surname>Dobson-Stone</surname><given-names>C</given-names></name><name><surname>Pierce</surname><given-names>K</given-names></name><etal/></person-group><article-title>Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder</article-title>. <source>Biol Psychiatry</source><year>2010</year>; <volume>67</volume>: <fpage>1217</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="pmid">20434135</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>E</given-names></name><name><surname>Rück</surname><given-names>C</given-names></name><name><surname>Lavebratt</surname><given-names>C</given-names></name><name><surname>Hedman</surname><given-names>E</given-names></name><name><surname>Schalling</surname><given-names>M</given-names></name><name><surname>Lindefors</surname><given-names>N</given-names></name><etal/></person-group><article-title>Genetic polymorphisms in monoamine systems and outcome of cognitive behavior therapy for social anxiety disorder</article-title>. <source>PLoS ONE</source><year>2013</year>; <volume>8</volume>: <fpage>e79015</fpage>.
<pub-id pub-id-type="pmid">24260145</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furmark</surname><given-names>T</given-names></name><name><surname>Carlbring</surname><given-names>P</given-names></name><name><surname>Hammer</surname><given-names>S</given-names></name><name><surname>Wahlgren</surname><given-names>I</given-names></name><name><surname>Ekselius</surname><given-names>L</given-names></name><name><surname>Eriksson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on the response to cognitive-behavior therapy in individuals with social anxiety disorder</article-title>. <source>Biol Psychiatry</source><year>2010</year>; <volume>67</volume> (<issue>9 suppl</issue>): <fpage>1S</fpage>–<lpage>271S</lpage>.
<pub-id pub-id-type="pmid">20381699</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedman</surname><given-names>E</given-names></name><name><surname>Andersson</surname><given-names>E</given-names></name><name><surname>Ljótsson</surname><given-names>B</given-names></name><name><surname>Andersson</surname><given-names>G</given-names></name><name><surname>Schalling</surname><given-names>M</given-names></name><name><surname>Lindefors</surname><given-names>N</given-names></name><etal/></person-group><article-title>Clinical and genetic outcome determinants of Internet-and group-based cognitive behavior therapy for social anxiety disorder</article-title>. <source>Acta Psychiatr Scand</source><year>2012</year>; <volume>126</volume>: <fpage>126</fpage>–<lpage>36</lpage>.
<pub-id pub-id-type="pmid">22320999</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knuts</surname><given-names>I</given-names></name><name><surname>Esquivel</surname><given-names>G</given-names></name><name><surname>Kenis</surname><given-names>G</given-names></name><name><surname>Overbeek</surname><given-names>T</given-names></name><name><surname>Leibold</surname><given-names>N</given-names></name><name><surname>Goossens</surname><given-names>L</given-names></name><etal/></person-group><article-title>Therapygenetics: 5-HTTLPR genotype predicts the response to exposure therapy for agoraphobia</article-title>. <source>Eur Neuropsychopharmacol</source><year>2014</year>; <volume>24</volume>: <fpage>1222</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="pmid">24906789</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonsdorf</surname><given-names>T</given-names></name><name><surname>Ruck</surname><given-names>C</given-names></name><name><surname>Bergstrom</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>G</given-names></name><name><surname>Ohman</surname><given-names>A</given-names></name><name><surname>Lindefors</surname><given-names>N</given-names></name><etal/></person-group><article-title>The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder</article-title>. <source>BMC Psychiatry</source><year>2010</year>; <volume>10</volume>: <fpage>99</fpage>.
<pub-id pub-id-type="pmid">21110842</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>JL</given-names></name><name><surname>Keers</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>S</given-names></name><name><surname>Coleman</surname><given-names>JR</given-names></name><name><surname>Breen</surname><given-names>G</given-names></name><name><surname>Arendt</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical predictors of response to cognitive-behavioral therapy in pediatric anxiety disorders: the Genes for Treatment (GxT) study</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source><year>2015</year>; <volume>54</volume>: <fpage>454</fpage>–<lpage>63</lpage>.
<pub-id pub-id-type="pmid">26004660</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>WK</given-names></name><name><surname>Albano</surname><given-names>AM</given-names></name></person-group><source>The Anxiety Disorders Interview Schedule for Children-IV (Child and Parent Versions)</source>.<publisher-name>Oxford University Press</publisher-name>, <year>1996</year>.
</mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Unnewehr</surname><given-names>S</given-names></name><name><surname>Margraf</surname><given-names>J</given-names></name></person-group><source>Kinder-DIPS für DSM-IV-TR. Diagnostisches Interview bei psychischen Störungen im Kindes-und Jugendalter [Child-DIPS for DSM-IV-TR. Diagnostic Interview for Psychiatric Disordes in Childhood and Adolescence]</source>. <publisher-name>Springer</publisher-name>, <year>2009</year>.
</mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>Curtis</surname><given-names>C</given-names></name><name><surname>Huckett</surname><given-names>L</given-names></name><name><surname>Mill</surname><given-names>J</given-names></name><name><surname>Craig</surname><given-names>IW</given-names></name></person-group><article-title>DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping</article-title>. <source>Behav Genet</source><year>2003</year>; <volume>33</volume>: <fpage>67</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="pmid">12645823</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>DNA Genotek</collab></person-group><source>Laboratory Protocol for Manual Purification of DNA from 0.5mL of Sample</source>. <publisher-name>DNS Genotek</publisher-name>, <year>2015</year>.
</mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Cherny</surname><given-names>SS</given-names></name><name><surname>Sham</surname><given-names>PC</given-names></name></person-group><article-title>Genetic power calculator: design of linkage and association genetic mapping studies of complex traits</article-title>. <source>Bioinformatics</source><year>2003</year>; <volume>19</volume>: <fpage>149</fpage>–<lpage>50</lpage>.
<pub-id pub-id-type="pmid">12499305</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>StataCorp</collab></person-group><source>Stata Statistical Software: release 11</source>. <publisher-name>Stata Corp LP</publisher-name>, <year>2009</year>.
</mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beevers</surname><given-names>CG</given-names></name><name><surname>McGeary</surname><given-names>JE</given-names></name></person-group><article-title>Therapygenetics: moving towards personalized psychotherapy treatment</article-title>. <source>Trends Cogn Sci</source>. <year>2011</year>; <volume>16</volume>: <fpage>11</fpage>–<lpage>2</lpage>.
<pub-id pub-id-type="pmid">22104133</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>LE</given-names></name><name><surname>Keller</surname><given-names>MC</given-names></name></person-group><article-title>A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry</article-title>. <source>Am J Psychiatry</source><year>2011</year>; <volume>168</volume>: <fpage>1041</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="pmid">21890791</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>JL</given-names></name><name><surname>Lester</surname><given-names>KJ</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Tropeano</surname><given-names>M</given-names></name><name><surname>Creswell</surname><given-names>C</given-names></name><name><surname>Collier</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Predicting outcomes following cognitive behaviour therapy in child anxiety disorders: the influence of genetic, demographic and clinical information</article-title>. <source>J Child Psychol Psychiatry</source>. <year>2013</year>; <volume>54</volume>: <fpage>1086</fpage>–<lpage>94</lpage>.
<pub-id pub-id-type="pmid">23772677</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
